HawkCell

About

HawkCell is a pioneering French deeptech company dedicated to revolutionizing animal healthcare through advanced medical imaging. Stemming from the scientific excellence of the French National Centre for Scientific Research (CNRS), the company specializes in augmenting Magnetic Resonance Imaging (MRI) technology specifically for veterinary and preclinical applications. At the core of HawkCell's innovation is a proprietary, patented plug-and-play system that integrates sophisticated hardware and software solutions. This system is designed to be manufacturer-agnostic, allowing it to adapt any human MRI machine for animal use. The hardware includes unique 3D-printed MRI coils tailored to diverse animal morphologies, ensuring the highest possible image quality and a special animal positioner that reduces the need for and duration of anesthesia, thereby minimizing risks to the animals. The company's software component, HawkAI, is a powerful post-processing algorithm driven by artificial intelligence. Utilizing convolutional neural networks, HawkAI significantly enhances image sharpness by up to 30% and accelerates scan times by half. This AI-powered denoising and quantitative analysis capability provides veterinarians and researchers with rapid, precise, and actionable data. HawkCell's expertise covers a wide array of medical fields, including neurology, oncology, cardiology, and musculoskeletal disorders. By providing meticulous in-vivo image acquisition, post-processing, and quantification, the company adheres to the stringent quality standards of the pharmaceutical industry and ethical principles for animal research. Following a successful Series A funding round, HawkCell is focused on expanding its operations internationally, particularly in the North American market, with the mission to close the gap between human and veterinary medicine and create a more efficient, sustainable healthcare ecosystem for all.